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Abstract
Aims/hypothesis Genome-wide association (GWA) studies
have identified hundreds of common genetic variants associ-
ated with obesity and type 2 diabetes. These studies have
usually focused on additive association tests. Identifying
deviations from additivity may provide new biological insights
and explain some of the missing heritability for these diseases.
Methods We performed a GWA study using a dominance
deviation model for BMI, obesity (29,925 cases) and type 2
diabetes (4,040 cases) in 120,286 individuals of British ances-
try from the UK Biobank study. We also investigated whether
single nucleotide polymorphisms previously shown to be
associated with these traits showed any enrichment for depar-
tures from additivity.
Results Known obesity-associated variants in FTO
showed strong evidence of deviation from additivity
(pDOMDEV= 3× 10
−5) through a recessive effect of the allele
associated with higher BMI. The average BMI of individ-
uals carrying zero, one or two BMI-raising alleles was
27.27 (95% CI 27.22, 27.31) kg/m2, 27.54 (95% CI 27.50,
27.58) kg/m2 and 28.07 (95% CI 28.00, 28.14) kg/m2,
respectively. A similar effect was observed in 105,643 in-
dividuals from the GIANT Consortium (pDOMDEV= 0.003;
meta-analysis pDOMDEV= 1× 10
−7). For type 2 diabetes, we
detected a recessive effect (pDOMDEV = 5 × 10
−4) at
CDKAL1. Relative to homozygous non-risk allele carriers,
homozygous risk allele carriers had an OR of 1.48 (95% CI
1.32, 1.65), while the heterozygous group had an OR of
1.06 (95% CI 0.99, 1.14), a result consistent with that of a
previous study. We did not identify any novel associations
at genome-wide significance.
Conclusions/interpretation Although we found no evidence
of widespread non-additive genetic effects contributing to
obesity and type 2 diabetes risk, we did find robust examples
of recessive effects at the FTO and CDKAL1 loci.
Access to research materials Summary statistics are available
at www.t2diabetesgenes.org and by request (a.r.wood@
exeter.ac.uk). All underlying data are available on
application from the UK Biobank.
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Introduction
Genome-wide association (GWA) studies have identified hun-
dreds of variants associated with obesity and type 2 diabetes
[1–9]. However, GWA studies of type 2 diabetes and obesity
have usually focused on testing additive models. An additive
model assumes that the disease risk of heterozygous individ-
uals is exactly halfway between those of the two homozygous
groups. Non-additive effects include dominant and recessive
effects. These effects are common inmonogenic disorders, but
there are only a few examples in common diseases and traits
[10]. For obesity and type 2 diabetes, the strongest evidence of
a non-additive effect is at the CDKAL1 locus, where a previ-
ous study demonstrated a recessive effect [11]. The GIANT
Consortium previously tested 32 BMI-associated variants for
deviations from the additive model but, overall, found no
evidence of deviation from additivity in 105,643 individuals
[5].
There are at least three reasons why it is important to test
for non-additive associations between common genetic vari-
ants and type 2 diabetes and obesity. First, a genome-wide
approach that tests alternative models could identify new
variants and candidate genes because the correct model may
have more statistical power. Second, the correct model of in-
heritance could explain more of the variation in the trait, and
hence account for some of the ‘missing heritability’ [12].
Third, the presence of recessive or dominant effects may in-
form follow-up physiological studies in vivo and in humans:
for example, by prioritising recruit-by-genotype efforts on
heterozygous as well as homozygous individuals.
The UK Biobank provides an excellent opportunity to test
for deviation from additivity in a single large cohort, as
genome-wide genetic data and detailed phenotypic data are
available in the initial release of data from over 120,000
British individuals [13]. In this study we used the UK
Biobank to perform GWA tests for deviations from the addi-
tive model for BMI, obesity and type 2 diabetes. We also
investigated whether evidence of deviation was present for
previously published single nucleotide polymorphisms
(SNPs) associated with these traits.
Methods
Samples
We used the data of 120,286 individuals of British descent
from the first UK Biobank genetic data release. Basic charac-
teristics are given in electronic supplementary material (ESM)
Table 1. British descent was defined as individuals who both
self-identified as white British and were confirmed as ances-
trally white using principal component analyses. Related indi-
viduals (third degree or higher) were estimated by the central
UK Biobank team and removed to provide the maximal unre-
lated set of individuals. Details of principal component
analyses and kinship analyses can be found in the official
UK Biobank genotyping document at http://biobank.ctsu.ox.
ac.uk/crystal/docs/genotyping_qc.pdf (accessed 1 December
2015).
Genotypes
We used imputed genotypes available from the UK Biobank
for association analyses. Briefly, phasing of individuals was
carried out by UK Biobank using SHAPEIT version 2; impu-
tation was performed using IMPUTE version 2 and a com-
bined 1000Genomes/UK10K reference panel. Full details can
be found in the official UK Biobank imputation document at
http://biobank.ctsu.ox.ac.uk/crystal/docs/impute_ukb_v1.pdf
(accessed 1 December 2015). Using the data of 120,286
individuals for analysis, variants were excluded if imputation
quality was <0.9, Hardy–Weinberg equilibrium was
p<1×10−6, or minor allele frequency (MAF) was <0.5%.
This quality control process resulted in 9,288,881 variants
for association analysis.
Selection of known SNPs
BMI and obesity We selected common genetic variants that
were associated with BMI in the most recent meta-analysis
from the GIANT Consortium [2, 5]. We limited the BMI
SNPs to one per locus (defined as a 500 kb window) and those
that were associated with BMI in the analysis of all European
ancestry individuals. In total, 72 SNPs previously associated
with BMI were analysed (ESM Table 2). This SNP list was
used for both BMI and obesity analyses.
Type 2 diabetesWe selected common genetic variants previ-
ously associated with type 2 diabetes in the Diabetes Genetics
Replication andMeta-Analysis (DIAGRAM) Consortium [3].
Details of the 66 type 2 diabetes SNPs are provided in ESM
Table 3.
Within-British principal component analysis
The UK Biobank study identified 120,286 individuals who
were both self-identified as white British and confirmed as
ancestrally white using genetics and principal component
analyses. The 120,286 individuals excluded third-degree or
closer relatives. We performed an additional round of princi-
pal component analysis on these 120,286 UK Biobank partic-
ipants. We selected 95,535 independent SNPs (pairwise
r2 < 0.1) directly genotyped with an MAF ≥2.5% and
missingness <1.5% across all UK Biobank participants with
genetic data available at the time of this study (n=152,732),
and with Hardy–Weinberg equilibrium p>1×10−6 within the
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white British participants. Principal components were subse-
quently generated using fast principal component analysis of
large-scale genome-wide data (flashpca) [14].
Phenotypes
BMI The UK Biobank provides two measures of BMI: one
calculated from weight (kg)/height (m2) and one using elec-
trical impedance. We excluded individuals with differences
>4.56 SDs between impedance and normal BMI measures
where both variables were available. If only one measure of
BMI was available this was used. We corrected BMI by
regressing age, sex, study centre and the first five within-
British principal components, and taking residual values. We
then inverse-normalised the residuals and used this phenotype
for analysis. A total of 119,688 white British individuals with
BMI and genetic data were available.
‘Obese’ and ‘severely obese’ categorical variables
Individuals were classified as obese if their BMI was
>30 kg/m2 (N= 29,925), and severely obese if their BMI
was (>40 kg/m2) (N=2,389). Controls for both were defined
as those with a BMI <25 kg/m2.
Type 2 diabetes Individuals were defined as having type 2
diabetes if they reported either type 2 diabetes or generic dia-
betes at the interview stage of the UK Biobank study.
Individuals were excluded if they reported insulin use within
the first year of diagnosis. Individuals reportedly diagnosed
under the age of 35 years or with no known age of diagnosis
were excluded, to limit the numbers of individuals with slow-
progressing autoimmune diabetes or monogenic forms.
Individuals diagnosed with diabetes within the last year of this
study were also excluded as we were unable to determine
whether they were using insulin within this time frame. A total
of 4,040 cases and 113,735 controls within the white British
subset of the UK Biobank with available genetic data were
identified.
Statistical analyses
Association testing We adjusted for genotyping chip at run-
time for the analyses of additive, dominance deviation, and
recessive models for both BMI and type 2 diabetes.
Association testing was performed through standard linear
and logistic regression methods applied to BMI and type 2
diabetes, respectively. Logistic regression models included
covariates at run-time. Type 2 diabetes was adjusted for age,
sex and the first five within-British principal components.
Deviation from the additive model If an allele operates
through a purely additive model then statistical evidence of a
dominant and/or recessive mechanism may still be detected
given counts of the three genotype classes. Similarly, if an
allele operates through a dominant or recessive mechanism
an additive model may also detect it. To detect genuine differ-
ences between additive and non-additive effects, we performed
a regression analysis against our traits of interest with a term
representing the additive model for genotypes (coded 0, 1 and
2 for the homozygote, heterozygous and alternate homozygote
groups, respectively) and a term representing the heterozygous
group (coded 0, 1 and 0). This test (known as the ‘dominance
deviation test’) determines whether the average trait value car-
ried by the heterozygous groups lies halfway between the two
homozygote groups as expected under an additive model.
Statistical threshold for GWA analysis To determine a
genome-wide significance threshold for genotypes available
in the UK Biobank we first estimated the number of indepen-
dent variants from those imputed with an imputation quality
≥0.4 and a minor allele count ≥5 within the 120,000 British
UK Biobank individuals. We took a conservative pairwise r2
threshold of 0.9 and this resulted in 15,005,727 variants esti-
mated as independent. A Bonferroni correction of this number
resulted in a GWA p value threshold of 3×10−9.
Statistical thresholds for known SNP setsWhen investigat-
ing previously published SNPs we applied a Bonferroni cor-
rection based on the number of SNPs (72 and 66 for BMI/
obesity and type 2 diabetes, respectively). This resulted in a p
value threshold of 7×10−4 and 8×10−4 for BMI/obesity status
and type 2 diabetes, respectively.
Power calculations Power calculations for BMI association
were performed using QUANTO [15] based on sample size,
variance explained and a significance level of 3 × 10−9.
Calculations of equivalent power for type 2 diabetes were
performed based on those of Yang et al [16].
Table 1 Summary statistics for
the most strongly associated im-
puted SNP (rs57292959) and
previously reported index SNP
(rs1421085) at the FTO locus
(r2= 0.91) with evidence of de-
parture from the additive model
Additive effects Deviation from additivity
SNP Locus Effect/other allele β SE p value β SE p value
rs1421085 FTO C/T 0.076 0.004 2 × 10−75 −0.025 0.006 3 × 10−5
rs57292959 FTO T/G 0.073 0.004 4 × 10−68 −0.030 0.006 4 × 10−7
Effect sizes are derived from BMI after inverse-normalisation of covariate-adjusted residuals
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Ethics: UK Biobank
This study was conducted using the UK Biobank resource.
Details of patient and public involvement in the UK
Biobank are available online (www.ukbiobank.ac.uk/about-
biobank-uk/ and www.ukbiobank.ac.uk/wp-content/uploads/
2011/07/Summary-EGF-consultation.pdf?phpMyAdmin=
trmKQlYdjjnQIgJ%2CfAzikMhEnx6). No patients were
specifically involved in setting the research question or the
outcome measures, nor were they involved in developing
plans for recruitment, design or implementation of this
study. No patients were asked to advise on interpretation or
writing up of results. There are no specific plans to
disseminate the results of the research to study participants,
but the UK Biobank disseminates key findings from projects
on its website.
Results
GWA study for deviation from additivity for BMI
We did not observe evidence of deviation from additivity at
any SNP for BMI at our genome-wide significance level of
p=3×10−9. ESM Figure 1 presents the genome-wide QQ plot
for the imputation-based dominance deviation test.
Alleles at the FTO locus have a partially recessive effect
on BMI and obesity status
Of the 72 known BMI variants, rs1421085, representing the
signal at FTO, was the only one reaching pDOMDEV<7×10
−4
(the Bonferroni threshold, given that we had tested 72 vari-
ants; Table 1 and ESM Table 4). This variant was recently
identified as the best candidate causal variant at FTO [2, 17].
This variant is also in very strong linkage disequilibrium
(r2 =0.91, D′>0.99) with rs57292959, which was the variant
with the third strongest evidence of deviation from additivity
in the GWA analysis (MAF=0.42; pDOMDEV=4×10
−7).
Homozygous carriers of the previously reported BMI-
raising allele (C at rs1421085) had an average BMI of
28.07 (95% CI 28.00, 28.14) kg/m2; heterozygotes had an
average BMI of 27.54 (95% CI 27.50, 27.58) kg/m2; and
Table 2 BMI values by genotype
group at the FTO locus
(rs1421085)
rs1421085 genotype group T/T T/C C/C
n 42,835 57,524 19,329
Mean (95% CI) 27.27 (27.22, 27.31) 27.54 (27.50, 27.58) 28.07 (28.00, 28.14)
SD 4.68 4.80 5.11
N= 119,688 white British individuals in the UK Biobank
The C allele is the BMI-raising allele
Units are in kg/m2
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Fig. 1 Average BMI and obesity ORs with 95% CIs for carriers of the
BMI-raising allele at the FTO locus represented by rs1421085. (a)
Average BMI within each of the three genotype classes. (b) Obesity risk
for heterozygous and homozygous carriers of the BMI-increasing allele.
(c) Severe obesity risk for the heterozygous and homozygous carriers of
the BMI-increasing allele
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homozygous carriers of the BMI-lowering allele had an aver-
age BMI of 27.27 (95% CI 27.22, 27.31) kg/m2 (Fig. 1a and
Table 2). While heterozygous carriers were still on average
more overweight than the common allele homozygote group,
the difference (0.27 kg/m2) was approximately half of the
difference observed between the heterozygote and minor
allele homozygote groups (0.53 kg/m2). Accounting for this
partially recessive effect only resulted in a small increase in
variance in BMI (an additional 0.01%).
The FTO locus also showed a similar pattern of deviation
from additivity in case–control analyses of obesity
(pDOMDEV= 0.001) and severe obesity (pDOMDEV= 0.003)
(Fig. 1b and c, and Table 3). The OR was stronger in homo-
zygous carriers of the risk allele than expected under an addi-
tive model. The observed OR for obese heterozygous carriers
of the BMI-raising allele was 1.15 (95%CI 1.12, 1.19). Under
the additive model we would expect an OR ~1.32 for obese
homozygous carriers, yet the observed OR was 1.48 (95% CI
1.41, 1.55). Similarly, the ORs observed in the severely obese
heterozygote and homozygous carriers were 1.28 (95% CI
1.16, 1.41) and 2.12 (95% CI 1.88, 2.38), respectively,
whereas under the additive model we would expect an OR
~1.64 for the homozygous carriers.
The partially recessive effect at FTO is present in 105,643
individuals from the GIANT Consortium
The GIANTConsortium previously tested for deviations from
additivity for 32 known BMI variants in 105,643 individuals
[5]. There was no overall evidence of deviations from additiv-
ity at these known loci; however, FTO did have a similar
partial recessive effect in this independent dataset, represented
by rs1558902: another proxy of rs1421085 (r2 >0.99, D′=1)
(pGIANT_DOMDEV = 0.003; β = −0.019; 95% CI −0.031,
−0.008). The negative direction of effect for the heterozygous
group in comparison with the two homozygous groups com-
bined was consistent with that observed in the UK Biobank
(Table 1) and indicative of a recessive effect for the BMI-
increasing allele. Meta-analysing the studies strengthened
the evidence of deviation from additivity (N = 225,143;
pMETA-ANALYSIS=1×10
−7).
No evidence of non-additive effects at other known BMI
variants
There was no evidence of deviation from additive effects for
the remaining 71 BMI variants (ESM Table 4). Based on the
72 BMI variants, we also showed that using an inverse-
normalised distribution of BMI produced very similar results
to those using BMI on its naturally skewed scale (ESM
Fig. 2).
GWA study for deviation from additivity for type 2
diabetes
We did not identify any variants deviating from additivity for
type 2 diabetes that reached genome-wide significance (ESM
Fig. 3).
Alleles at the CDKAL1 locus have a recessive effect
for type 2 diabetes
Of the 66 known type 2 diabetes variants we only found
evidence of deviation from additivity for the SNP rs7756992 at
the CDKAL1 locus (MAF=0.27; pDOMDEV=5×10
−4) (Fig. 2,
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Fig. 2 ORs and 95% CIs for heterozygous and homozygous carriers of
the CDKAL1 type 2 diabetes risk allele against the reference non-risk
allele homozygous group
Table 3 ORs for ‘obese’ and ‘severely obese’ classifications by genotype group at the FTO locus (rs1421085)
Class Additive Dominance deviation
from additivity
T/T vs T/C T/C vs C/C T/T vs C/C
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Obese 1.20 (1.18, 1.23) 2 × 10−60 0.95 (0.92, 0.98) 0.001 1.15 (1.12, 1.19) 2 × 10−16 1.28 (1.23, 1.34) 3 × 10−28 1.48 (1.41, 1.55) 2 × 10−62
Severely
obese
1.44 (1.36, 1.53) 2 × 10−33 0.88 (0.81, 0.96) 0.003 1.28 (1.16, 1.41) 7 × 10−07 1.66 (1.49, 1.85) 2 × 10−20 2.12 (1.88, 2.38) 2 × 10−36
The C allele is the risk-increasing allele
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Table 4 and ESM Table 5). The genotype OR was stronger in
homozygous carriers of the risk allele than expected under an
additive model (Table 5). The observed OR within the heterozy-
gous carriers of the risk-increasing allele was 1.06 (95% CI 0.99,
1.14; p=0.08), which is smaller than the expected OR of ~1.22
for heterozygous carriers under an additivemodel. This finding is
consistent with a previous study by deCODE genetics
(Reykjavik, Iceland) that showed evidence of this SNP having
a recessive pattern of association with type 2 diabetes risk [11].
We found no evidence of deviation from additivity for any of the
remaining known type 2 diabetes variants.
Discussion
Our analyses of 120,286 UKBiobank individuals suggest that
most genetic variants associated with BMI and type 2 diabetes
operate through a per-allele additive effect. Our findings sug-
gest that dominant and recessive effects at common variants
have a minimal role in explaining variation in BMI and risk of
obesity and type 2 diabetes. Our results are consistent with a
previous smaller study of 6,715 individuals that concluded
that deviations from additivity contribute little to missing
heritability for a wide range of traits [18]. There were excep-
tions for the FTO–BMI association and the CDKAL1–type 2
diabetes association.
The 16% of individuals carrying two copies of the BMI-
raising allele at the FTO locus had more than twice the
expected BMI difference compared with individuals carrying
no BMI-raising alleles than would have been expected under a
purely additive model. Assuming an average height in males
of 1.78 m, it is equivalent to homozygous carriers of the BMI-
increasing allele being 2.53 kg heavier than homozygous
carriers of the opposite allele, whereas heterozygous carriers
would be only 0.86 kg heavier. Previous studies have shown
that the vast majority of this increased weight is fat mass [1].
The results are also consistent with a study of the FTO variant
in polycystic ovary syndrome [19]. For type 2 diabetes, we
found evidence of a recessive effect at theCDKAL1 locus. The
evidence that heterozygous carriers of the risk allele were at
increased risk of type 2 diabetes was minimal and, combined
with previous data from the deCODE study, suggests the true
biological effect at this locus is recessive. Although account-
ing for non-additive effects at these loci only explained a small
amount of additional variation in risk of obesity and type 2
diabetes, understanding why these associations demonstrate
non-additivitymay provide new insights into biological mech-
anisms at these loci.
A strength of our study is that we used a single large,
relatively homogeneous dataset with full access to
individual-level genotype and phenotype data. We had
>80% power to detect dominance deviation from additivity,
explaining 0.04% of the phenotypic variance at p=3×10−9.
This is equivalent to being able to detect a purely recessive
effect of 0.4 kg/m2 for a BMI allele with a frequency of 0.25,
for example. We had less power for the type 2 diabetes
analysis (approximately ×6.5 less [16]). To have equivalent
power to our BMI analysis we would require approximately
26,000 cases and 740,000 controls. Our analyses show how
single large studies such as the UK Biobank will provide
added value to existing meta-analyses approaches in GWA
studies.
Our analyses have some limitations. We analysed imputed
variants, and our statistical power to detect deviations from
additivity might have been reduced if variants were not per-
fectly captured and/or we analysed imperfect markers for
causal alleles. Non-biological explanations for the non-
additive effects include ‘haplotype effects’ due to linkage dis-
equilibriumwith other causal alleles. In such situations, alleles
of SNPs showing evidence of non-additivity are partially
correlated with a much stronger causal SNP with an additive
effect [20, 21]. This is unlikely to be the case at the FTO or
CDKAL1 loci. These loci have been studied extensively
through re-sequencing and fine-mapping efforts and no
Table 5 Type 2 diabetes ORs by
genotype group at the CDKAL1
locus (rs7756992)
Additive effect A/A vs A/G A/G vs G/G A/A vs G/G
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
1.15 (1.10, 1.21) 1 × 10−08 1.06 (0.99, 1.14) 0.077 1.39 (1.24, 1.56) 1 × 10−8 1.48 (1.32, 1.65) 6 × 10−12
N= 117,775 white British individuals in the UK Biobank
The G allele is the type 2 diabetes risk-increasing allele
Table 4 Summary statistics for
rs7756992 at the CDKAL1 locus
showing evidence of deviation
from additivity
Additive effect Dominance deviation
SNP Locus Risk/other allele OR SE p value OR SE p value
rs7756992 CDKAL1 G/A 1.15 0.025 1 × 10−8 0.87 0.038 5 × 10−4
The effect allele is the allele observed to be the risk-raising allele under the additive test
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substantially stronger individual variants have been identified;
and for FTO, rs1421085 was recently proposed as the most
likely causal variant [17]. The rs1421085 SNP disrupts a bind-
ing site for ARID5B, which increases the expression of IRX3
and IRX5 during adipocyte differentiation. This results in the
production ofmore white adipocytes, a reduction inmitochon-
drial thermogenesis and an increase in lipid storage, although
it is not clear why this would lead to non-additive effects on
BMI.
The detection of non-additive genetic effects for BMI is
potentially complicated by the skewed distribution of BMI.
Effects that seem recessive could be artefacts of the skewed
nature of the BMI distribution, as variation in BMI is wider
towards the more overweight end of the distribution. To limit
this effect we inverse-normalised BMI and performed addi-
tional sensitivity analyses (including ‘robust regression’—an
alternative to ‘least squares regression’) that account for dif-
ferent variances of a trait, which may be the case for FTO [22]
(data not shown), to limit the influence of the skewed distri-
bution. We found, however, no evidence that BMI-increasing
alleles were more likely to have recessive effects than BMI-
lowering alleles (ESMTable 4 and ESMFig. 4). Alternatively,
artificially truncating the BMI distribution into a normal dis-
tribution could reduce the power to detect recessive effects of
BMI-increasing alleles. However, we saw very little reduction
in statistical confidence of known BMI associations when
using the inverse-normalised scale compared with the natural
BMI scale.
In conclusion, we have performed tests of deviation from
additivity for BMI, obesity and type 2 diabetes. Overall, there
was little evidence of dominant and recessive effects.
However, we found replicable examples of non-additive
effects at FTO on BMI and obesity, and at CDKAL1 on type
2 diabetes risk. Recessive effects have implications for the
mechanism of action of these loci but do not explain appre-
ciably more of the ‘missing heritability’.
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